[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360495-105":59,"doc-detail-360495-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","prognostic-scores-and-risk-stratification-of-myeloproliferative-neoplasms-2026-updates-narrative-review-and-practical-guide","Prognostic Scores and Risk Stratification of Myeloproliferative Neoplasms: 2026 Updates - narrative review and practical guide","","Myeloproliferative neoplasms (MPNs) are heterogenous myeloid disorders including polycythemia vera, essential thrombocythemia, and myelofibrosis, each associated with meaningful morbidity, thrombotic risk, and reduced survival. Therapy selection depends on individualized risk assessment, making prognostication central to clinical management. Recent years have brought major advances in prognostic and risk-stratification models, including incorporation of molecular markers. This narrative review summarizes these prognostic tools and provides practical guidance for using them to support personalized treatment strategies for MPN patients.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prognostic-scores-and-risk-stratification-of-myeloproliferative-neoplasms-2026-updates-narrative-review-and-practical-guide/360495/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prognostic-scores-and-risk-stratification-of-myeloproliferative-neoplasms-2026-updates-narrative-review-and-practical-guide/360495.png","ImageObject",300,407,{"name":92,"@type":93},"Grenda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What are myeloproliferative neoplasms (MPNs) and which conditions are included?","Question",{"text":113,"@type":114},"MPNs are long-term blood diseases that include polycythemia vera, essential thrombocythemia, and myelofibrosis. They share underlying driver mutations but differ in clinical and prognostic features.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why is risk assessment important for treating MPN patients?",{"text":118,"@type":114},"Selecting therapy depends on patients’ risk assessment, and accurate prognostication helps clinicians guide management and personalize treatment goals. Risk stratification can also reduce complications such as thrombosis and disease transformation.",{"name":120,"@type":111,"acceptedAnswer":121},"How do modern risk stratification models differ from traditional models?",{"text":122,"@type":114},"Traditional scores mainly rely on clinical variables, while newer models incorporate molecular markers and advances in precision medicine. Newer tools aim to refine prediction of outcomes and better support personalized strategies.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},360495,1790233228,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971474921005,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Review  \nPrognostic Scores and Risk Stratification of Myeloproliferative Neoplasms: 2026 Updates  \nNoor Al-Zubaidi†, Estela Ruiz†, Natalia Curto-Garcia  and Priya Sriskandarajah *  \nAcademic Editors: Qiang Jeremy Wen, Wei Chen and Fei Li  \nReceived: 5 May 2026  \nRevised: 20 May 2026  \nAccepted: 22 May 2026  \nPublished: 25 May 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nGuy’s and St Thomas’ Hospital, London SE1 9RT, UK; [noor.alzubaidi1@nhs.net](noor.alzubaidi1@nhs.net) (N.A.-Z.);  \nestela.ruiz@carm.es (E.R.); [natalia.curto-garcia@nhs.net](natalia.curto-garcia@nhs.net) (N.C.-G.)  \n* [Correspondence: priya.sriskandarajah@nhs.net](Correspondence: priya.sriskandarajah@nhs.net)  \n† These authors contributed equally to this work.  \nSimple Summary  \nMyeloproliferative neoplasms (MPNs) are a group of long-term blood diseases that affect the bone marrow. These include polycythemia vera, essential thrombocythemia, and myelofibrosis. Although these conditions differ, they can be associated with significant symptom burden, and in the long-term they result in an increased risk of disease progression and shortened life expectancy. Treatment decisions for MPN patients require careful consideration and thus accurate risk assessment is an important component of their management. Major advances have led to the development of multiple risk scores that predict outcomes to help patients and healthcare professionals decide on management approaches. However, it can be challenging to delineate which of these risk assessments should be used in clinical practice. In this narrative review, we aim to provide an overview of these risk prediction tools and a practical guide on how these can be utilized to support personalized treatment decisions for MPN patients.  \nAbstract  \nMyeloproliferative neoplasms (MPNs) are a heterogenous group of myeloid disorders including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF) . All these conditions can be associated with significant morbidity including increased risk of thrombotic events as well as reduced survival. Selecting therapy is dependent on patients’risk assessment and thus prognostication is vital in the management of these conditions. There have been significant developments in prognostic and risk stratification models for MPNs over the last few years, including incorporation of molecular markers. This narrative review article aims to summarize these prognostic models and provide practical advice on how clinicians can utilize these tools to develop personalized treatment strategies for MPN patients.  \nKeywords: myeloproliferative neoplasms; risk stratification; prognosis; molecular  \n1. Introduction  \nMPN disorders are caused by gene mutations affecting the JAK-STAT signaling pathway. These mutations lead to constant activation of the JAK2 pathway which controlshematopoietic cellular proliferation, survival and differentiation. The main driver mutations are JAK2V617F, MPL and CALR. The understanding of driver mutations has shifted MPN disorders into genetically defined cancers shaping diagnostic workup, prognostication and tailored treatments. Although MPNs share these common driver muta-  \ntions, they differ greatly in symptom burden, predicted disease outcome and leukemic transformation risk.  \nPolycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) demonstrate distinct clinical, hematological, and histopathological characteristics [1–5] . PV is characterized by erythrocytosis, ET by sustained thrombocytosis, and MF by progressive bone marrow fibrosis, cytopenias, constitutional symptoms, and extramedullary hematopoiesis. These disease-specific features contribute to differences in symptom burden, thrombotic risk, leukemic transformation, and overall prognosis.  \nThrombosis is a leading ","cbCaimkAjQR9a0vc","https://ap.wps.com/l/cbCaimkAjQR9a0vc","pdf",331098,"English","# Introduction\n## Driver mutations and disease heterogeneity\n## Thrombosis burden and clinical implications\n## Traditional versus newer risk scores\n## Classification of risk tools in MPNs\n## Machine learning and AI in risk prediction","[{\"question\":\"What are myeloproliferative neoplasms (MPNs) and which conditions are included?\",\"answer\":\"MPNs are long-term blood diseases that include polycythemia vera, essential thrombocythemia, and myelofibrosis. They share underlying driver mutations but differ in clinical and prognostic features.\"},{\"question\":\"Why is risk assessment important for treating MPN patients?\",\"answer\":\"Selecting therapy depends on patients’ risk assessment, and accurate prognostication helps clinicians guide management and personalize treatment goals. Risk stratification can also reduce complications such as thrombosis and disease transformation.\"},{\"question\":\"How do modern risk stratification models differ from traditional models?\",\"answer\":\"Traditional scores mainly rely on clinical variables, while newer models incorporate molecular markers and advances in precision medicine. Newer tools aim to refine prediction of outcomes and better support personalized strategies.\"}]","Prognostic Scores and Risk Stratification of Myeloproliferative Neoplasms: 2026 Updates - narrative review and practical guide | PDF",1790140257,48,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f46a68b0b1026b49767f81d1d40fca2.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58eae161a6e95f094afabe774cff4161.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b044176f81f5d647c17cd1e5f2897f67.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f008f7f6a11cf202edc8dfad37dc2377.webp",980,1385]